Poncelet C, Walker F, Madelenat P, Bringuier A F, Scoazec J Y, Feldmann G, Darai E
Laboratoire de Biologie Cellulaire, INSERM U327, Faculté de Medecine Xavier Bichat Université Paris, Paris, France.
Hum Pathol. 2001 Nov;32(11):1190-6. doi: 10.1053/hupa.2001.28935.
Alterations of CD44 proteins, a family of cell adhesion molecule, have been linked with tumorigenesis, carcinogenesis, and prognosis in various neoplasms. Our aims were to evaluate and compare CD44 isoforms expression patterns in normal myometrium, uterine leiomyomas, and leiomyosarcomas and to correlate CD44 expression with clinicopathologic parameters. Fresh (n = 15) and formalin-fixed, paraffin-embedded (n = 76) tissues samples of myometrium, leiomyomas, and leiomyosarcomas were used for immunoblotting and immunohistochemistry, respectively. Semiquantitative evaluation was made after immunostaining. Monoclonal antibodies were used. By immunoblotting in myometrium and leiomyomas samples, we observed a band at 85 kd, corresponding to the apparent molecular weight of CD44s, and bands at 140 kd with the monoclonal antibodies against CD44v3 and CD44v6. In leiomyosarcomas, CD44s and CD44v6 were detected, but not CD44v3. By immunohistochemistry, decreased CD44s expression was found in leiomyomas and leiomyosarcomas (73.9% +/- 16.6% and 82.1% +/- 20.7%, respectively) compared with myometrium (97.3% +/- 6.2%; P < .0001). No CD44v6 staining was detected in myometrium, leiomyomas, and leiomyosarcomas. No CD44v3 expression was detected in leiomyosarcomas, whereas myometrium and leiomyomas expressed CD44v3. For the diagnosis of leiomyosarcoma, the absence of CD44v3 staining had a sensitivity, specificity, and positive and negative predictive values of 100%. In patients with recurrence of leiomyosarcomas, CD44s expression was decreased (P = .03). We conclude that CD44s immunostaining in leiomyosarcomas may have prognostic significance. The loss of CD44v3 expression could be used as a putative diagnostic tool for uterine leiomyosarcomas.
CD44蛋白家族作为一类细胞黏附分子,其改变与多种肿瘤的发生、发展及预后相关。本研究旨在评估并比较CD44亚型在正常子宫肌层、子宫平滑肌瘤及平滑肌肉瘤中的表达模式,并将CD44表达与临床病理参数进行关联分析。分别采用新鲜组织样本(n = 15)及福尔马林固定、石蜡包埋组织样本(n = 76)进行免疫印迹及免疫组化检测,免疫染色后进行半定量评估,使用单克隆抗体。通过免疫印迹法检测子宫肌层和平滑肌瘤样本,观察到一条85 kd的条带,对应CD44s的表观分子量,以及针对CD44v3和CD44v6的单克隆抗体所识别的140 kd条带。在平滑肌肉瘤中,检测到CD44s和CD44v6,但未检测到CD44v3。免疫组化结果显示,与子宫肌层(97.3% +/- 6.2%)相比,平滑肌瘤和平滑肌肉瘤中CD44s表达降低(分别为73.9% +/- 16.6%和82.1% +/- 20.7%;P <.0001)。在子宫肌层、平滑肌瘤和平滑肌肉瘤中均未检测到CD44v6染色。平滑肌肉瘤中未检测到CD44v3表达,而子宫肌层和平滑肌瘤表达CD44v3。对于平滑肌肉瘤的诊断,CD44v3染色缺失的敏感性、特异性、阳性预测值和阴性预测值均为100%。在平滑肌肉瘤复发患者中,CD44s表达降低(P =.03)。我们得出结论,平滑肌肉瘤中CD44s免疫染色可能具有预后意义。CD44v3表达缺失可作为子宫平滑肌肉瘤的一种潜在诊断工具。